GENMAB Inactive Instrument
Genmab Stock Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
| Sales 2024 * | 19.82B 2.9B | Sales 2025 * | 23.64B 3.46B | Capitalization | 117B 17.13B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.71B 688M | Net income 2025 * | 6.55B 958M | EV / Sales 2024 * | 4.6 x |
| Net cash position 2024 * | 25.89B 3.79B | Net cash position 2025 * | 32.21B 4.71B | EV / Sales 2025 * | 3.59 x |
| P/E ratio 2024 * |
25.7
x | P/E ratio 2025 * |
18.7
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
| Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 15-12-31 |
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
2024-08-01
- Q2 2024 Earnings Release
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +20.12% | 126B | |
| +25.25% | 119B | |
| +25.56% | 27.95B | |
| -19.51% | 20.5B | |
| -15.63% | 16.1B | |
| -46.67% | 14.97B | |
| +11.89% | 14.84B | |
| +57.74% | 14.38B | |
| +147.53% | 12.37B |
